Artykuły w czasopismach na temat „Drug-reduced regimens”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Drug-reduced regimens”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
VanScoy, Brian, Jennifer McCauley, Sujata M. Bhavnani, Evelyn J. Ellis-Grosse i Paul G. Ambrose. "Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model". Antimicrobial Agents and Chemotherapy 60, nr 9 (6.06.2016): 5141–45. http://dx.doi.org/10.1128/aac.00355-16.
Pełny tekst źródłaAng, Zen Yang, Kit Yee Cheah, Nadiah B. Abdullah, Safawati B. Samsuri, Siao Hui Lee, Andrew WH Yem i Malathi AP Sriraman. "Parenteral cytotoxic drug wastage at a tertiary hospital in Kuala Lumpur: How much and why?" Journal of Oncology Pharmacy Practice 26, nr 6 (6.12.2019): 1306–17. http://dx.doi.org/10.1177/1078155219891209.
Pełny tekst źródłaVia, Laura E., Kathleen England, Danielle M. Weiner, Daniel Schimel, Matthew D. Zimmerman, Emmanuel Dayao, Ray Y. Chen i in. "A Sterilizing Tuberculosis Treatment Regimen Is Associated with Faster Clearance of Bacteria in Cavitary Lesions in Marmosets". Antimicrobial Agents and Chemotherapy 59, nr 7 (4.05.2015): 4181–89. http://dx.doi.org/10.1128/aac.00115-15.
Pełny tekst źródłaRhee, Soo-Yon, Philip M. Grant, Philip L. Tzou, Geoffrey Barrow, P. Richard Harrigan, John P. A. Ioannidis i Robert W. Shafer. "A systematic review of the genetic mechanisms of dolutegravir resistance". Journal of Antimicrobial Chemotherapy 74, nr 11 (5.07.2019): 3135–49. http://dx.doi.org/10.1093/jac/dkz256.
Pełny tekst źródłaTasneen, Rokeya, Fabrice Betoudji, Sandeep Tyagi, Si-Yang Li, Kathy Williams, Paul J. Converse, Véronique Dartois i in. "Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis". Antimicrobial Agents and Chemotherapy 60, nr 1 (26.10.2015): 270–77. http://dx.doi.org/10.1128/aac.01691-15.
Pełny tekst źródłaHawkins, Trevor, Wenoah Veikley, Lucie Durand-Gasselin, Darius Babusis, Y. Sunila Reddy, John F. Flaherty i Adrian S. Ray. "Intracellular Nucleotide Levels during Coadministration of Tenofovir Disoproxil Fumarate and Didanosine in HIV-1-Infected Patients". Antimicrobial Agents and Chemotherapy 55, nr 4 (31.01.2011): 1549–55. http://dx.doi.org/10.1128/aac.00910-10.
Pełny tekst źródłaZhdanov, Konstantin V., Oleg V. Maltsev, Kristina V. Kasyanenko, Konstantin V. Kozlov, Vitalii S. Sukachev, Nikolai I. Lvov, Valerian V. Sharabkhanov i Alexander A. Litvinov. "Clinical efficiency and safety of riamilovir under various dosage regimens for treatment of acute respiratory viral infections in adults". Terapevticheskii arkhiv 95, nr 11 (22.12.2023): 930–36. http://dx.doi.org/10.26442/00403660.2023.11.202471.
Pełny tekst źródłaDutta, Noton K., Michael L. Pinn i Petros C. Karakousis. "Reduced Emergence of Isoniazid Resistance with Concurrent Use of Thioridazine against Acute Murine Tuberculosis". Antimicrobial Agents and Chemotherapy 58, nr 7 (5.05.2014): 4048–53. http://dx.doi.org/10.1128/aac.02981-14.
Pełny tekst źródłaJung, H., R. Medina, N. Castro, T. Corona i J. Sotelo. "Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen." Antimicrobial Agents and Chemotherapy 41, nr 6 (czerwiec 1997): 1256–59. http://dx.doi.org/10.1128/aac.41.6.1256.
Pełny tekst źródłaTyczyńska, Agata, Marcela Krzysława Krzempek, Alexander Jorge Cortez, Artur Jurczyszyn, Katarzyna Godlewska, Hanna Ciepłuch, Edyta Subocz i in. "The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age". Cancers 15, nr 13 (2.07.2023): 3469. http://dx.doi.org/10.3390/cancers15133469.
Pełny tekst źródłaJung, Hyun Joo, i Nami McCarty. "Stem-Like Tumor Cells Confer Drug Resistant Properties to Mantle Cell Lymphoma". Blood 116, nr 21 (19.11.2010): 1840. http://dx.doi.org/10.1182/blood.v116.21.1840.1840.
Pełny tekst źródłaCórdoba, J., N. M. Coronado-Álvarez, D. Parra i J. Parra-Ruiz. "In VitroActivities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii". Antimicrobial Agents and Chemotherapy 59, nr 12 (14.09.2015): 7316–19. http://dx.doi.org/10.1128/aac.00493-15.
Pełny tekst źródłaLubberman, Floor, Hans Gelderblom, Paul Hamberg, Walter Vervenne, Sasja F. Mulder, Frank Jansman, Angela Colbers i in. "A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?" Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 4564. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4564.
Pełny tekst źródłaShank, Kaitlyn R., Priya Koppikar, Neha Bhagwat, Matthew D. Keller, Franziska Michor, Ross L. Levine i Laura De Vargas Roditi. "Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN Patients". Blood 124, nr 21 (6.12.2014): 911. http://dx.doi.org/10.1182/blood.v124.21.911.911.
Pełny tekst źródłaBhatti, Laveeza, i Jay Gladstein. "Once-Daily Nevirapine XR". Journal of the International Association of Physicians in AIDS Care 11, nr 6 (27.08.2012): 369–73. http://dx.doi.org/10.1177/1545109712456427.
Pełny tekst źródłaRao, Gauri G., Neang S. Ly, Curtis E. Haas, Samira Garonzik, Alan Forrest, Jurgen B. Bulitta, Pamela A. Kelchlin i in. "New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease". Antimicrobial Agents and Chemotherapy 58, nr 3 (16.12.2013): 1381–88. http://dx.doi.org/10.1128/aac.00327-13.
Pełny tekst źródłaHenegar, Cassidy, Emilio Letang, Ruolan Wang, Charles Hicks, Dainielle Fox, Bryn Jones, Annemiek de Ruiter i Vani Vannappagari. "A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings". Viruses 15, nr 12 (14.12.2023): 2426. http://dx.doi.org/10.3390/v15122426.
Pełny tekst źródłaSvensson, Elin M., Francesca Aweeka, Jeong-Gun Park, Florence Marzan, Kelly E. Dooley i Mats O. Karlsson. "Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis". Antimicrobial Agents and Chemotherapy 57, nr 6 (9.04.2013): 2780–87. http://dx.doi.org/10.1128/aac.00191-13.
Pełny tekst źródłaCraddock, Charles. "Pharmacological methods to reduce disease recurrence". Hematology 2013, nr 1 (6.12.2013): 63–69. http://dx.doi.org/10.1182/asheducation-2013.1.63.
Pełny tekst źródłaAziz, Muhammad Tahir. "Drug Interaction Exposures in an Intensive Care Unit: AntihypertensivePopulation". Journal of Applied Pharmacy 7 (2015): 41. http://dx.doi.org/10.21065/19204159.7.41.
Pełny tekst źródłaGonzalez-Juarrero, Mercedes, Lisa K. Woolhiser, Elizabeth Brooks, Mary Ann DeGroote i Anne J. Lenaerts. "Mouse Model for Efficacy Testing of Antituberculosis Agents via Intrapulmonary Delivery". Antimicrobial Agents and Chemotherapy 56, nr 7 (30.04.2012): 3957–59. http://dx.doi.org/10.1128/aac.00464-12.
Pełny tekst źródłaLu, Hong, i Sara Rosenbaum. "Developmental Pharmacokinetics in Pediatric Populations". Journal of Pediatric Pharmacology and Therapeutics 19, nr 4 (1.10.2014): 262–76. http://dx.doi.org/10.5863/1551-6776-19.4.262.
Pełny tekst źródłaOvsyankina, E. S., L. V. Panova, E. A. Krushinskaya, O. A. Piskunova i F. G. Poluektova. "ON THE QUESTION OF REDUCED DURATION OF PULMONARY TB TREATMENT IN ADOLESCENTS WITH DRUG SUSCEPTIBILITY DETERMINATION DURING TREATMENT". Вестник ЦНИИТ 7, nr 2 (2023): 67–72. http://dx.doi.org/10.57014/2587-6678-2023-7-2-67-72.
Pełny tekst źródłaTitov, K. S., E. V. Shutov, A. A. Alimov, S. S. Lebedev, A. A. Kirichek i G. M. Zapirov. "Nephrotoxicity of combination drug therapy in metastatic renal cancer". Cancer Urology 19, nr 3 (16.11.2023): 153–62. http://dx.doi.org/10.17650/1726-9776-2023-19-3-153-162.
Pełny tekst źródłaHarris, Taylor N., i Lindsey R. Buscemi. "Evaluation of treatment simplification strategies in patients living with HIV with multi-drug resistance". Therapeutic Advances in Infectious Disease 10 (styczeń 2023): 204993612211498. http://dx.doi.org/10.1177/20499361221149869.
Pełny tekst źródłaKukurika, А. V. "Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis". FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15, nr 3 (9.10.2022): 353–62. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2022.131.
Pełny tekst źródłaJames, Lyndon P., Fayette Klaassen, Sedona Sweeney, Jennifer Furin, Molly F. Franke, Reza Yaesoubi, Dumitru Chesov i in. "Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis". PLOS Medicine 21, nr 5 (3.05.2024): e1004401. http://dx.doi.org/10.1371/journal.pmed.1004401.
Pełny tekst źródłaBada, Florence O., Nick Blok, Evaezi Okpokoro, Saswata Dutt, Christopher Akolo, Patrick Dakum i Alash’le Abimiku. "Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria". PLOS ONE 15, nr 12 (1.12.2020): e0241065. http://dx.doi.org/10.1371/journal.pone.0241065.
Pełny tekst źródłaKelly, W. K., H. I. Scher, M. Mazumdar, D. Pfister, T. Curley, C. Leibertz, L. Cohen, V. Vlamis, A. Dnistrian i M. Schwartz. "Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer." Journal of Clinical Oncology 13, nr 9 (wrzesień 1995): 2214–22. http://dx.doi.org/10.1200/jco.1995.13.9.2214.
Pełny tekst źródłaBeelen, DW, K. Quabeck, U. Graeven, HG Sayer, HK Mahmoud i UW Schaefer. "Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia [see comments]". Blood 74, nr 5 (1.10.1989): 1507–16. http://dx.doi.org/10.1182/blood.v74.5.1507.1507.
Pełny tekst źródłaBeelen, DW, K. Quabeck, U. Graeven, HG Sayer, HK Mahmoud i UW Schaefer. "Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia [see comments]". Blood 74, nr 5 (1.10.1989): 1507–16. http://dx.doi.org/10.1182/blood.v74.5.1507.bloodjournal7451507.
Pełny tekst źródłaDing, Yajun, Robert Glaubius i Ume Abbas. "Drug Resistance After Failure of WHO Recommended First-Line Antiretroviral Regimen for Adult HIV-1 Infection in South Africa: A Modeling Analysis". Open Forum Infectious Diseases 4, suppl_1 (2017): S424. http://dx.doi.org/10.1093/ofid/ofx163.1067.
Pełny tekst źródłaTaft, David, Tarang Vora, Chen Ren, Patrick S. Zbyszewski, Joseph Morgan, Michael E. Petrone, Steven M. Fruchtman i Manoj Maniar. "Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine". Blood 132, Supplement 1 (29.11.2018): 4379. http://dx.doi.org/10.1182/blood-2018-99-118463.
Pełny tekst źródłaFekadu, Ginenus, Jiaqi Yao i Joyce H. S. You. "Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis". PLOS ONE 17, nr 8 (5.08.2022): e0272770. http://dx.doi.org/10.1371/journal.pone.0272770.
Pełny tekst źródłaLiu, Ying, Samyukta Mullangi, Xiaoxue Chen, Timothy Pham, David Joseph Debono, Michael Jordan Fisch, Aliza Gordon i Dawn L. Hershman. "Association between oncology clinical pathway utilization and quality and cost outcomes in patients with metastatic solid tumors." Journal of Clinical Oncology 40, nr 28_suppl (1.10.2022): 430. http://dx.doi.org/10.1200/jco.2022.40.28_suppl.430.
Pełny tekst źródłaShang, Shaobin, Crystal A. Shanley, Megan L. Caraway, Eileen A. Orme, Marcela Henao-Tamayo, Laurel Hascall-Dove, David Ackart i in. "Activities of TMC207, Rifampin, and Pyrazinamide againstMycobacterium tuberculosisInfection in Guinea Pigs". Antimicrobial Agents and Chemotherapy 55, nr 1 (11.10.2010): 124–31. http://dx.doi.org/10.1128/aac.00978-10.
Pełny tekst źródłaKaufmann, Gilbert R., Nina Khanna, Rainer Weber, Luc Perrin, Hansjakob Furrer, Matthias Cavassini, Bruno Ledergerber i in. "Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection". Antiviral Therapy 9, nr 2 (luty 2004): 263–74. http://dx.doi.org/10.1177/135965350400900212.
Pełny tekst źródłaVaughan, William P., Amy G. Nance i Donna E. Salzman. "Improving Dosing Precision in Buslfan (BU) Based Preparative Regimens for Hematopoietic Stem Cell Transplantation (HSCT)." Blood 104, nr 11 (16.11.2004): 1148. http://dx.doi.org/10.1182/blood.v104.11.1148.1148.
Pełny tekst źródłaGray, Adam Thorburn, Liana Macpherson, Ffion Carlin, Bianca Sossen, Alexandra S. Richards, Sandra V. Kik, Rein M. G. J. Houben i in. "Treatment for radiographically active, sputum culture-negative pulmonary tuberculosis: A systematic review and meta-analysis". PLOS ONE 18, nr 11 (16.11.2023): e0293535. http://dx.doi.org/10.1371/journal.pone.0293535.
Pełny tekst źródłaSoeny, Kabir, Barbara Bogacka i Byron Jones. "Dose optimisation with simultaneous pharmacokinetic estimation in adaptive clinical trials". Statistical Methods in Medical Research 29, nr 4 (7.06.2019): 1149–66. http://dx.doi.org/10.1177/0962280219852582.
Pełny tekst źródłaNsengiyumva, Ntwali Placide, Jonathon R. Campbell, Olivia Oxlade, Juan F. Vesga, Christian Lienhardt, Anete Trajman, Dennis Falzon, Saskia Den Boon, Nimalan Arinaminpathy i Kevin Schwartzman. "Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness". PLOS Medicine 19, nr 6 (13.06.2022): e1004032. http://dx.doi.org/10.1371/journal.pmed.1004032.
Pełny tekst źródłaMcCruden, D. C., T. E. Hilditch, J. M. C. Connell i W. D. Alexander. "Kinetics of [123I]iodide uptake and discharge by perchlorate in studies of inhibition of iodide binding by antithyroid drugs". Acta Endocrinologica 110, nr 4 (grudzień 1985): 499–504. http://dx.doi.org/10.1530/acta.0.1100499.
Pełny tekst źródłaChalchal, Hafsah, Vinita Dhir, Kalina Abrol, Michelle Boyce, Michelle Delbaere, Ashish Masurekar, Mike Kennah i in. "Favorable Outcomes with Low Dose Anti Thymocyte Globulin Based Graft Versus Host Disease Prophylaxis after Mismatched Unrelated Donor Allogenic Hematopoietic Cell Transplantation". Blood 142, Supplement 1 (28.11.2023): 7002. http://dx.doi.org/10.1182/blood-2023-182274.
Pełny tekst źródłaSiddiqui, Abdul Aziz, Kazi Najamus-saqib Khan, Arafat Ali Farooqui, Muhammad Saad Farooqi, Muhammad Junaid Tariq i Faiz Anwer. "Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review". Blood 134, Supplement_1 (13.11.2019): 5574. http://dx.doi.org/10.1182/blood-2019-132095.
Pełny tekst źródłaWinters, Mark A., i Thomas C. Merigan. "Variants Other than Aspartic Acid at Codon 69 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene Affect Susceptibility to Nucleoside Analogs". Antimicrobial Agents and Chemotherapy 45, nr 8 (1.08.2001): 2276–79. http://dx.doi.org/10.1128/aac.45.8.2276-2279.2001.
Pełny tekst źródłaHan, Win Min, Wiriya Mahikul, Thomas Pouplin, Saranath Lawpoolsri, Lisa J. White i Wirichada Pan-Ngum. "Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach". PLOS ONE 16, nr 3 (26.03.2021): e0248846. http://dx.doi.org/10.1371/journal.pone.0248846.
Pełny tekst źródłaRolsma, Stephanie L., Andrew G. Sokolow, Guohua An, Nick Fishbane, William Fissell, Kenan Gu, Natalia Jimenez i in. "Are We Dosing Correctly? Population Pharmacokinetic Modeling of Cefepime, Piperacillin-Tazobactam, and Meropenem in Individuals with Cystic Fibrosis". Journal of the Pediatric Infectious Diseases Society 12, Supplement_1 (1.11.2023): S8. http://dx.doi.org/10.1093/jpids/piad070.015.
Pełny tekst źródłaStone, Chris, Mounir Ait-Khaled, Charles Craig, Philip Griffin i Margaret Tisdale. "Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine". Antimicrobial Agents and Chemotherapy 48, nr 4 (kwiecień 2004): 1413–15. http://dx.doi.org/10.1128/aac.48.4.1413-1415.2004.
Pełny tekst źródłaFedorin, Andrey Aleksandrovich, Nikolay Alexandrovich Pudovkin, Yulia Rifovna Borodina i Sergey Dmitrievich Klyukin. "Comparative effectiveness of flea allergic dermatitis treatment regimens in dogs and cats". Agrarian Scientific Journal, nr 8 (10.09.2021): 78–81. http://dx.doi.org/10.28983/asj.y2021i8pp78-81.
Pełny tekst źródłaYu, Zaikuan J., Eric P. Mosher i Namandjé N. Bumpus. "Pharmacogenomics of Antiretroviral Drug Metabolism and Transport". Annual Review of Pharmacology and Toxicology 61, nr 1 (6.01.2021): 565–85. http://dx.doi.org/10.1146/annurev-pharmtox-021320-111248.
Pełny tekst źródła